Stock of the Week: AstraZeneca

Britain's second largest company is now part of a global tug-of-war over coronavirus vaccines, but analysts say it's got much more to offer than life-saving jabs

James Gard 12 March, 2021 | 11:21AM
Facebook Twitter LinkedIn

Stock of the Week

Our stock of the week featured four FTSE 100 companies that are ranked highly for gender diversity, and vaccine pioneer AstraZeneca (AZN) has come out on top, as voted for by our Twitter followers.

AstraZeneca was one of the first global pharmaceutical companies to bring out a workable coronavirus vaccine, a development that changed the narrative on how the world plans to exit from the pandemic. The Oxford-AstraZeneca vaccine, as it’s known, has already been given to more than 11 million British people and is central to the UK Government’s plans to leave lockdown. This cause for optimism has been clouded in recent weeks by concerns over side effects and the politicisation of the vaccine rollout. Some European countries temporarily suspended the rollout of the Astra jab, with Germany only just approving the vaccine for use in the over-65s, while Italy blocked a shipment of vaccines to Australia.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

See All Our Stock of the Week Posts

Catch up Now

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

James Gard  is content editor for


© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement